UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
12b-25
Commission
File Number 0-54433
NOTIFICATION
OF LATE FILING
(Check
One):
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q
[ ]
Form 10-D [ ] Form N-CEN [ ] Form N-CSR
For
Period Ended: September 30, 2019
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
For
the Transition Period Ended:
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A
PART
I
REGISTRANT
INFORMATION
MariMed
Inc.
Full
Name of Registrant
Not
Applicable
Former
Name if Applicable
10
Oceana Way
Address
of Principal Executive Office (Street and Number)
Norwood,
Massachusetts 02062
City,
State and Zip Code
PART
II
RULES
12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
[X]
|
|
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort
or expense;
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form
N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c)
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the transition report or portion
thereof, could not be filed within the prescribed time period.
MariMed
Inc. (“we”, “our” or “us”) has been unable to file the Quarterly Report on Form 10-Q for the
quarter ended September 30, 2019 (the “Report”) by November 12, 2019 without unreasonable effort or expense due a
fire at a GenCanna Global Inc. facility that has prevented GenCanna Global Inc. from timely providing us with certain financial
information necessary to finalize the financial statements to be included in our Report. We believe that the Report will be available
for filing on or before November 18, 2019.
PART
IV
OTHER
INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
|
Jon
R. Levine
|
|
(617)
795-5140
|
|
|
(Name)
|
|
(Area
Code) (Telephone Number)
|
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s). [X] Yes [ ] No
(3)
Is it anticipated that any significant change in results of operation for the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject report or portion thereof? [X] Yes [ ] No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
The
following are the anticipated changes in results of operations for the three and nine month periods ended September 30, 2019
and 2018, respectively:
Total
revenues for the three and nine month periods ended September 30, 2019 are expected to be approximately, $11.2 million and $40.4
million, respectively, compared to approximately, $3.4 million and $8.4 million, respectively, for the same periods in 2018.
Cost
of revenues for the three and nine month periods ended September 30, 2019 are expected to be approximately, $6.5 million and $24.5
million, respectively, compared to approximately, $1.5 million and $3.3 million, respectively, for the same periods in 2018.
Operating expenses for the three
and nine month periods ended September 30, 2019 are expected to be approximately, $3.7 million and $9.8 million, respectively,
compared to approximately, $2.4 million and $5.5 million, respectively, for the same periods in 2018.
As
a result of the foregoing, operating income for the three and nine month periods ended September 30, 2019 is expected to
be approximately, $1.0 million and $6.2 million, respectively, compared to operating losses of approximately,
$549,000 and $417,000, respectively, for the same periods in 2018.
MariMed
Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
November 13, 2019
|
By:
|
/s/
Jon R. Levine
|
|
Name:
|
Jon
R. Levine
|
|
Title:
|
Chief
Financial Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name
and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf
of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority
to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).
GENERAL
INSTRUCTIONS
1.
This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act
of 1934.
2.
One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities
and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act.
The information contained in or filed with the form will be made a matter of public record in the Commission files.
3.
A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class
of securities of the registrant is registered.
4.
Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished.
The form shall be clearly identified as an amended notification.
5.
Electronic Filers: This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties.
Filers unable to submit reports within the time period prescribed due to difficulties in electronic filing should comply with
either Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing
date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this chapter).
6.Interactive
data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive
Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time
period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024